Market Place
Sourcing Support
Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI
28 Nov 2024 //
INDPHARMAPOST
Shorla gains FDA nod for 1st oral version of Novartis` Gleevec
27 Nov 2024 //
BUSINESSWIRE
Kura Oncology Reports Preclinical Data For Ziftomenib In GIST
24 Oct 2024 //
GLOBENEWSWIRE
Kura Oncology Announces FDA Clearance Of IND For Ziftomenib In GIST
08 Aug 2024 //
GLOBENEWSWIRE
Aerovate`s stock plummets after sole product fails in PAH trial
18 Jun 2024 //
FIERCE PHARMA
Inhibikase Announces Selection of the Bioequivalent Dose of IkT-001
22 Jun 2023 //
PR NEWSWIRE
Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901
11 May 2023 //
GLOBENEWSWIRE
Aerami to Investor Day with Leading Experts in Pulmonary Hypertension
03 Apr 2023 //
GLOBENEWSWIRE
Aerami Therapeutics Announces Expansion of the AER-901 Development Program
23 Feb 2023 //
GLOBENEWSWIRE
Takeda`s Iclusig tops Novartis` Gleevec decisively in Ph+ALL
15 Feb 2023 //
FIERCE PHARMA
Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901
21 Dec 2022 //
GLOBENEWSWIRE
Qilu Pharmaceutical`s Generic Imatinib Mesylate Receives Approval in US
21 Jun 2022 //
FDA
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix
26 May 2022 //
FIERCEPHARMA
Qilu`s Generic Imatinib Mesylate Receives Approval in the U.S.
11 Feb 2022 //
FDA
Deciphera Presents Results from INTRIGUE Phase 3 Study at ASCO
24 Jan 2022 //
BUSINESSWIRE
Deciphera Announces Approval of QINLOCK in UK
21 Dec 2021 //
BUSINESSWIRE
Deciphera Receives EC Approval of QINLOCK for Gastrointestinal Stromal Tumor
22 Nov 2021 //
BUSINESSWIRE
Tenax Therapeutics Reports Q3 2021 Results and Provides Business Update
16 Nov 2021 //
BUSINESSWIRE
Novartis receives approval for third-generation leukaemia therapy
03 Nov 2021 //
PMLIVE
Novartis scores new CML OK for `wild card` STAMP inhibitor
30 Oct 2021 //
ENDPTS
Daiichi jettisons ADC after flunking early solid tumor test
30 Oct 2021 //
FIERCEBIOTECH
BRD9 inhibition promotes PUMA-dependent apoptosis and effect of imatinib
18 Oct 2021 //
NATURE
Deciphera Announces Approval of QINLOCK in Switzerland
12 Oct 2021 //
BUSINESSWIRE
FDA Clears Tenax`s IND for Imatinib in Pulmonary Arterial Hypertension
06 Oct 2021 //
BUSINESSWIRE
Koanaa`s Imatinib Koanaa (imatinib mesylate) Receives Approval in Europe
22 Sep 2021 //
EMA
Deciphera Announces Positive CHMP Opinion for QINLOCK®
17 Sep 2021 //
BUSINESSWIRE
Pimitespib Prolongs Survival in Refractory Gastrointestinal Stromal Tumour
07 Jun 2021 //
FIRSTWORLDPHARMA
Enforcement Report - Week of March 3, 2021
03 Mar 2021 //
FDA
Enforcement Report - Week of December 16, 2020
16 Dec 2020 //
FDA
#ASH20: Out to shake up CML once again, Novartis lays out head-to-head between
08 Dec 2020 //
ENDPTS
Novartis finds a third-generation scion to an aging Gleevec
25 Aug 2020 //
ENDPTS
RA Capital-backed Aerovate launches with $72.6M to treat PAH with a repurposed
06 Aug 2020 //
ENDPTS
Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 M
06 Aug 2020 //
GLOBENEWSWIRE
Eugia Pharma`s Generic Methotrexate Sodium Receives Approval in US
30 Jul 2020 //
FDA
Aerami Therapeutics Signs a Global License Agreement with Vectura Group
08 Jun 2020 //
PRESS RELEASE
Vectura signs agreement with Aerami Therapeutics Inc.
08 Jun 2020 //
GLOBENEWSWIRE
FDA Approves First Drug for Fourth-Line Treatment of Gastrointestinal
15 May 2020 //
PRNEWSWIRE
AI VIVO seeks pharma, biotech collaboration partners to advance drug candidates
10 May 2020 //
MEDICAL
Zydus Pharmaceutical`s Generic Imatinib Mesylate Receives Approval in US
11 Apr 2020 //
FDA
Zydus Cadila gets USFDA nod to market generic cancer drug
09 Apr 2020 //
INDIATIMES
Cadila Healthcare share price hits 52-week high on USFDA nod for cancer drug
08 Apr 2020 //
MONEYCONTROL
Shilpa Medicare`s subsidiary gets UK regulator nod for anti-cancer drug
06 Apr 2020 //
MONEYCONTROL
China expands drug bulk-buy program, puts pressure on pharma firms
25 Sep 2019 //
REUTERS
Deciphera success sets up 2-horse race in gastrointestinal cancer
14 Aug 2019 //
BIOPHARMADIVE
Deciphera soars as phase 3 cancer data tee up FDA filing
13 Aug 2019 //
FIERCE BIOTECH
Armas Expands Generic Portfolio with Launches of Capecitabine and Imatinib
08 Apr 2019 //
PR NEWSWIRE
Natco Pharma’s Generic Imatinib Mesylat Receives Approval In US
05 Mar 2019 //
FDA
Medicare Part D no match for runaway specialty drug costs: study
07 Feb 2019 //
REUTERS
Deciphera CBO Morl talks lines of therapy for kinase inhibitor ripretinib
11 Jan 2019 //
FIERCE BIOTECH
Blueprint posts `impressive` data for lead candidate, but investors tepid
17 Nov 2018 //
BIOPHARMA DIVE
Letters and drug alerts sent to healthcare professionals in September 2018
11 Oct 2018 //
GOV UK
Letters and drug alerts sent to healthcare professionals in September 2018
11 Oct 2018 //
GOV UK
Letters and drug alerts sent to healthcare professionals in September 2018
11 Oct 2018 //
GOV UK
EMA Withdraws Marketing Authorisation of Teva BV`s Imatinib Generic
10 Oct 2018 //
EMA
EMA Assessment Report of Teva BV`s Imatinib Generic
09 Oct 2018 //
EMA
Imatinib 400mg Capsules (3 x 10) PL 36390/0180 : Company-led recall
22 Sep 2018 //
GOV-UK
The Curious Case Of Gleevec Pricing
13 Sep 2018 //
FORBES
Gleevec antitrust suits against Novartis fall short again in appeals
22 Aug 2018 //
FIERCE PHARMA
Dr Reddys Labs` Generic Imatinib Mesylate Receives Approval in US
17 Aug 2018 //
FDA
Trump battle over drug prices heats up
23 Jul 2018 //
THE HILL
